Vitamin B12 levels are not affected by radioiodine ablation of the thyroid.

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as an observational study.

Radioiodine administered for the treatment of hyperthyroidism and thyroid cancer can be taken up by many non-thyroid tissues which express sodium iodide symporter.

Though gastric mucosa takes up radioiodine, its impact on parietal cell has not been evaluated.

The aim of the present study was to compare vitamin B12 and homocysteine concentrations in patients with thyroid disorders treated by radioiodine ablation with those in control population without radioiodine exposure.

Who Took Part

According to the abstract, 35 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Patients with Graves' disease, toxic multinodular goiter (TMNG), toxic adenoma (TA) or differentiated thyroid cancer (DTC) who had received 131I were included as "patients".

Healthy persons and patients having Graves' disease but without exposure to radioiodine were recruited as "controls".

How the Study Was Run

A total of 35 patients and 35 controls were included.

Patients were divided into Graves' disease and non-Graves' disease (TMNG, TA, DTC) groups.

Graves' disease patients were compared with Graves' disease controls while non-Graves' disease patients were compared with healthy controls.

What Was Measured

The subject headings attached to it are Adenoma, Carcinoma, Papillary, Follicular, Case-Control Studies, Cross-Sectional Studies, Goiter, Nodular, Graves Disease and Homocysteine.

What This Means in Plain Language

This is an observational study of Cyanocobalamin (Vitamin B12) in 35 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Endocrine regulations), a journal based in Germany.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.